AlphaTON Capital Corp and its subsidiary, Tarus Therapeutics, present a new poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The work shows how selective adenosine A2B receptor inhibition has a direct anti-tumor effect in mesothelioma cells. This research supports the development of the selective A2B receptor antagonist TT-4 for mesothelioma treatment. Initial preclinical results have shown promising activity, and the company plans to start first-in-human evaluation in Q1 2026. These findings strengthen the case for targeting the A2B receptor in mesothelioma therapy.

The company is also advancing other programs, including TT-10 (A2A receptor antagonist) in phase 1 dose escalation for advanced solid tumors. The poster presentation details the effects of ADORA2B inhibition in mesothelioma cells on PD-L1 expression and AKT signaling. AlphaTON Capital is a digital asset treasury company focused on TON tokens and developing the Telegram ecosystem. Led by CEO Brittany Kaiser and CIO Enzo Villani, the company is actively involved in drug development to target checkpoint resistance pathways for improved patient outcomes.

Read more at GlobeNewswire: AlphaTON Capital and Cyncado Therapeutics Share New